Obchod Amicus - FOLD CFD
Pridať medzi obľúbené- Zhrnutie
- Historické dáta
- Udalosti
- Výkaz ziskov a strát
- Súvahový list
- Peňažný tok
- Vlastníctvo
Podmienky obchodovania
| Rozpätie | 0.07 | ||||||||
|
Nočný poplatok dlhej pozície
Long position overnight fee
Prejsť na platformu | -0.025457% | ||||||||
|
Nočný poplatok krátkej pozície
Short position overnight fee
Prejsť na platformu | 0.003235% | ||||||||
| Nočný poplatok | 21:00 (UTC) | ||||||||
| Minimálne množstvo na obchodovanie | 1 | ||||||||
| Mena | USD | ||||||||
| Marža | 20% | ||||||||
| Burza cenných papierov | United States of America | ||||||||
| Provízia pri predaji | 0% |
*Information provided by Capital.com
Amicus Therapeutics Inc ESG Risk Ratings
High Medium Low Negligible
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Kľúčové štatistiky
| Predchádzajúce Zavrieť* | 10.57 |
| Otvoriť* | 10.37 |
| 1-ročná zmena* | -3.36% |
| Denný rozsah* | 10.37 - 10.84 |
| Rozsah 52 týždňov | 7.78-13.84 |
| Priemerný objem (10 dní) | 2.42M |
| Priemerný objem (3 mesiace) | 52.69M |
| Trhová kapitalizácia | 3.59B |
| Pomer P/E | -100.00K |
| Zdieľa mimoriadne | 284.58M |
| Výnosy | 336.79M |
| EPS | -0.70 |
| Dividenda (udalosť %) | N/A |
| Beta | 0.80 |
| Ďalší dátum zárobku | Aug 2, 2023 |
Všetky údaje poskytuje spoločnosť Refinitiv, okrem údajov označených hviezdičkou, čo sú *údaje poskytnuté Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Zatvorenie | Change | Change (%) | Otvorenie | High | Low |
|---|---|---|---|---|---|---|
| Jun 29, 2022 | 10.76 | 0.27 | 2.57% | 10.49 | 10.87 | 10.30 |
| Jun 28, 2022 | 10.57 | -0.13 | -1.21% | 10.70 | 10.97 | 10.42 |
| Jun 27, 2022 | 10.77 | 0.06 | 0.56% | 10.71 | 11.04 | 10.43 |
| Jun 24, 2022 | 11.08 | 0.11 | 1.00% | 10.97 | 11.09 | 10.43 |
| Jun 23, 2022 | 10.88 | 1.06 | 10.79% | 9.82 | 10.99 | 9.82 |
| Jun 22, 2022 | 9.95 | 0.30 | 3.11% | 9.65 | 10.30 | 9.62 |
| Jun 21, 2022 | 9.84 | 0.36 | 3.80% | 9.48 | 10.15 | 9.38 |
| Jun 17, 2022 | 9.32 | 0.86 | 10.17% | 8.46 | 9.42 | 8.44 |
| Jun 16, 2022 | 8.36 | 0.48 | 6.09% | 7.88 | 8.44 | 7.79 |
| Jun 15, 2022 | 8.14 | 0.35 | 4.49% | 7.79 | 8.30 | 7.79 |
| Jun 14, 2022 | 7.90 | 0.20 | 2.60% | 7.70 | 8.02 | 7.70 |
| Jun 13, 2022 | 7.86 | -0.17 | -2.12% | 8.03 | 8.17 | 7.75 |
| Jun 10, 2022 | 8.33 | 0.17 | 2.08% | 8.16 | 8.48 | 8.16 |
| Jun 9, 2022 | 8.53 | 0.09 | 1.07% | 8.44 | 8.90 | 8.44 |
| Jun 8, 2022 | 8.74 | 0.43 | 5.17% | 8.31 | 8.86 | 8.26 |
| Jun 7, 2022 | 8.39 | 0.72 | 9.39% | 7.67 | 8.42 | 7.67 |
| Jun 6, 2022 | 7.85 | -0.28 | -3.44% | 8.13 | 8.27 | 7.76 |
| Jun 3, 2022 | 8.14 | 0.77 | 10.45% | 7.37 | 8.18 | 7.37 |
| Jun 2, 2022 | 7.73 | 0.22 | 2.93% | 7.51 | 7.78 | 7.45 |
| Jun 1, 2022 | 7.60 | 0.21 | 2.84% | 7.39 | 7.77 | 7.39 |
Amicus Events
| Čas (UTC) (UTC) | Krajina | Udalosť |
|---|---|---|
| Wednesday, August 2, 2023 | ||
| Čas (UTC) (UTC) 12:30 | Krajina US
| Udalosť Q2 2023 Amicus Therapeutics Inc Earnings Release Q2 2023 Amicus Therapeutics Inc Earnings ReleaseForecast -Previous - |
| Monday, November 6, 2023 | ||
| Čas (UTC) (UTC) 13:30 | Krajina US
| Udalosť Q3 2023 Amicus Therapeutics Inc Earnings Release Q3 2023 Amicus Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Výročný
- Štvrťročne
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Celkové príjmy | 329.233 | 305.514 | 260.886 | 182.237 | 91.245 |
| Výnosy | 329.233 | 305.514 | 260.886 | 182.237 | 91.245 |
| Náklady na výnosy, celkom | 38.599 | 34.466 | 31.044 | 21.963 | 14.404 |
| Hrubý zisk | 290.634 | 271.048 | 229.842 | 160.274 | 76.841 |
| Celkové prevádzkové náklady | 541.353 | 512.205 | 515.16 | 526.898 | 420.022 |
| Predaj/Všeobecné/Správca. Náklady, Celkom | 213.041 | 192.71 | 156.407 | 169.861 | 127.2 |
| Výskum a vývoj | 276.677 | 272.049 | 308.443 | 286.378 | 270.902 |
| Depreciation / Amortization | 5.342 | 6.209 | 8.846 | 4.775 | 4.216 |
| Nezvyčajné výdavky (príjem) | 6.616 | 0.257 | 7.276 | 40.624 | 0 |
| Other Operating Expenses, Total | 1.078 | 6.514 | 3.144 | 3.297 | 3.3 |
| Prevádzkový príjem | -212.12 | -206.691 | -254.274 | -344.661 | -328.777 |
| Úrokový príjem (výdavky), čistý neprevádzkový | -34.095 | -31.962 | -19.199 | -8.623 | -14.68 |
| Iné, Net | 4.176 | -2.901 | -0.781 | -2.626 | -5.632 |
| Čistý príjem pred zdanením | -242.039 | -241.554 | -274.254 | -355.91 | -349.089 |
| Čistý príjem po zdanení | -236.568 | -250.46 | -276.852 | -356.388 | -349.095 |
| Čistý príjem pred extra. Položky | -236.568 | -250.46 | -276.852 | -356.388 | -349.095 |
| Čistý príjem | -236.568 | -250.46 | -276.852 | -356.388 | -348.995 |
| Príjem k dispozícii bežnému Extra. Položky | -236.568 | -250.46 | -276.852 | -356.388 | -349.095 |
| Príjem k dispozícii bežnému vr. Extra. Položky | -236.568 | -250.46 | -276.852 | -356.388 | -348.995 |
| Zriedený čistý príjem | -236.568 | -250.46 | -276.852 | -356.388 | -348.995 |
| Zriedený vážený priemer akcií | 289.057 | 271.422 | 258.867 | 240.421 | 185.79 |
| Zriedený EPS s výnimkou mimoriadnych položiek | -0.81841 | -0.92277 | -1.06947 | -1.48235 | -1.87898 |
| Zriedený normalizovaný EPS | -0.80354 | -0.92215 | -1.0512 | -1.37252 | -1.52912 |
| Celkom mimoriadne položky | 0 | 0.1 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Celkové príjmy | 86.27 | 88.096 | 81.691 | 80.731 | 78.715 |
| Výnosy | 86.27 | 88.096 | 81.691 | 80.731 | 78.715 |
| Náklady na výnosy, celkom | 6.942 | 9.384 | 13.436 | 8.197 | 7.582 |
| Hrubý zisk | 79.328 | 78.712 | 68.255 | 72.534 | 71.133 |
| Celkové prevádzkové náklady | 123.906 | 130.424 | 115.531 | 141.344 | 154.054 |
| Predaj/Všeobecné/Správca. Náklady, Celkom | 73.957 | 54.274 | 47.272 | 53.379 | 58.116 |
| Výskum a vývoj | 41.499 | 63.871 | 52.97 | 78.319 | 81.517 |
| Depreciation / Amortization | 1.257 | 1.311 | 1.286 | 1.334 | 1.411 |
| Other Operating Expenses, Total | 0.251 | 1.584 | 0.567 | 0.115 | -1.188 |
| Prevádzkový príjem | -37.636 | -42.328 | -33.84 | -60.613 | -75.339 |
| Úrokový príjem (výdavky), čistý neprevádzkový | -9.698 | -9.123 | -9.057 | -7.901 | -8.014 |
| Iné, Net | -5.885 | -18.628 | 13.634 | 7.268 | 1.902 |
| Čistý príjem pred zdanením | -53.219 | -70.079 | -29.263 | -61.246 | -81.451 |
| Čistý príjem po zdanení | -52.932 | -55.865 | -33.286 | -62.157 | -85.26 |
| Čistý príjem pred extra. Položky | -52.932 | -55.865 | -33.286 | -62.157 | -85.26 |
| Čistý príjem | -52.932 | -55.865 | -33.286 | -62.157 | -85.26 |
| Príjem k dispozícii bežnému Extra. Položky | -52.932 | -55.865 | -33.286 | -62.157 | -85.26 |
| Príjem k dispozícii bežnému vr. Extra. Položky | -52.932 | -55.865 | -33.286 | -62.157 | -85.26 |
| Zriedený čistý príjem | -52.932 | -55.865 | -33.286 | -62.157 | -85.26 |
| Zriedený vážený priemer akcií | 291.337 | 289.706 | 289.224 | 291.971 | 288.482 |
| Zriedený EPS s výnimkou mimoriadnych položiek | -0.18169 | -0.19283 | -0.11509 | -0.21289 | -0.29555 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Zriedený normalizovaný EPS | -0.18169 | -0.19283 | -0.11509 | -0.21289 | -0.28064 |
| Nezvyčajné výdavky (príjem) | 0 | 0 | 0 | 0 | 6.616 |
- Výročný
- Štvrťročne
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Celkové aktíva | 423.816 | 596.834 | 579.469 | 520.073 | 551.096 |
| Hotovosť a krátkodobé investície | 293.595 | 482.496 | 483.269 | 452.74 | 504.152 |
| Hotovosť a ekvivalenty | 148.813 | 245.197 | 163.24 | 142.837 | 79.749 |
| Krátkodobé investície | 144.782 | 237.299 | 320.029 | 309.903 | 424.403 |
| Pohľadávky celkom, netto | 66.196 | 52.672 | 46.923 | 33.284 | 21.962 |
| Accounts Receivable - Trade, Net | 66.196 | 52.672 | 46.923 | 33.284 | 21.962 |
| Total Inventory | 23.816 | 26.818 | 19.556 | 14.041 | 8.39 |
| Prepaid Expenses | 40.209 | 34.848 | 29.721 | 20.008 | 16.592 |
| Total Assets | 724.167 | 905.14 | 886.52 | 850.207 | 789.951 |
| Property/Plant/Equipment, Total - Net | 60.312 | 63.082 | 67.159 | 81.02 | 11.375 |
| Property/Plant/Equipment, Total - Gross | 82.593 | 82.964 | 89.22 | 103.966 | 27.046 |
| Accumulated Depreciation, Total | -22.281 | -19.882 | -22.061 | -22.946 | -15.671 |
| Goodwill, Net | 197.797 | 197.797 | 197.797 | 197.797 | 197.797 |
| Intangibles, Net | 23 | 23 | 23 | 23 | 23 |
| Other Long Term Assets, Total | 19.242 | 24.427 | 19.095 | 28.317 | 6.683 |
| Total Current Liabilities | 139.018 | 145.975 | 129.676 | 128.812 | 86.125 |
| Accounts Payable | 15.413 | 21.513 | 17.063 | 21.722 | 6.606 |
| Accrued Expenses | 88.66 | 95.21 | 88.442 | 68.852 | 36.188 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | |||||
| Other Current Liabilities, Total | 34.945 | 29.252 | 24.171 | 8.55 | 5.5 |
| Total Liabilities | 601.12 | 597.771 | 600.14 | 373.782 | 447.039 |
| Total Long Term Debt | 391.99 | 389.357 | 389.254 | 149.505 | 321.74 |
| Long Term Debt | 391.99 | 389.357 | 389.254 | 149.505 | 321.74 |
| Deferred Income Tax | 4.939 | 4.93 | 4.896 | 5.051 | 6.465 |
| Other Liabilities, Total | 65.173 | 57.509 | 76.314 | 90.414 | 32.709 |
| Total Equity | 123.047 | 307.369 | 286.38 | 476.425 | 342.912 |
| Common Stock | 2.815 | 2.808 | 2.65 | 2.598 | 1.942 |
| Additional Paid-In Capital | 2664.74 | 2595.42 | 2308.58 | 2227.23 | 1740.06 |
| Retained Earnings (Accumulated Deficit) | -2532.41 | -2295.84 | -2033.07 | -1756.22 | -1399.16 |
| Unrealized Gain (Loss) | -0.116 | -0.27 | -0.185 | 0.04 | -0.427 |
| Other Equity, Total | -11.989 | 5.251 | 8.412 | 2.785 | 0.495 |
| Total Liabilities & Shareholders’ Equity | 724.167 | 905.14 | 886.52 | 850.207 | 789.951 |
| Total Common Shares Outstanding | 281.108 | 278.913 | 262.063 | 255.418 | 189.384 |
| Payable/Accrued | 29.688 | 37.831 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Celkové aktíva | 399.697 | 423.816 | 458.539 | 497.643 | 518.9 |
| Hotovosť a krátkodobé investície | 267.109 | 293.595 | 354.7 | 386.841 | 411.195 |
| Hotovosť a ekvivalenty | 160.602 | 148.813 | 277.592 | 235.639 | 233.317 |
| Krátkodobé investície | 106.507 | 144.782 | 77.108 | 151.202 | 177.878 |
| Pohľadávky celkom, netto | 68.178 | 66.196 | 52.303 | 52.556 | 52.421 |
| Accounts Receivable - Trade, Net | 68.178 | 66.196 | 52.303 | 52.556 | 52.421 |
| Total Inventory | 27.004 | 23.816 | 13.272 | 20.879 | 24.324 |
| Prepaid Expenses | 37.406 | 40.209 | 38.264 | 37.367 | 30.96 |
| Total Assets | 700.519 | 724.167 | 759.528 | 800.589 | 826.938 |
| Property/Plant/Equipment, Total - Net | 59.889 | 60.312 | 62.32 | 64.104 | 62.053 |
| Property/Plant/Equipment, Total - Gross | 54.307 | 53.059 | 55.786 | 55.845 | 55.51 |
| Accumulated Depreciation, Total | -22.901 | -22.281 | -23.337 | -22.188 | -20.966 |
| Goodwill, Net | 197.797 | 197.797 | 197.797 | 197.797 | 197.797 |
| Intangibles, Net | 22.964 | 23 | 23 | 23 | 23 |
| Other Long Term Assets, Total | 20.172 | 19.242 | 17.872 | 18.045 | 25.188 |
| Total Current Liabilities | 138.385 | 139.018 | 164.65 | 164.625 | 129.699 |
| Accounts Payable | 24.965 | 15.413 | 12.046 | 23.113 | 22.914 |
| Accrued Expenses | 100.752 | 102.188 | 132.771 | 122.246 | 87.634 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 12.668 | 21.417 | 19.833 | 19.266 | 19.151 |
| Total Liabilities | 597.946 | 601.12 | 626.963 | 627.164 | 588.321 |
| Total Long Term Debt | 392.658 | 391.99 | 391.319 | 390.652 | 389.994 |
| Long Term Debt | 392.658 | 391.99 | 391.319 | 390.652 | 389.994 |
| Deferred Income Tax | 0 | 4.939 | 4.93 | 4.93 | 4.93 |
| Other Liabilities, Total | 66.903 | 65.173 | 66.064 | 66.957 | 63.698 |
| Total Equity | 102.573 | 123.047 | 132.565 | 173.425 | 238.617 |
| Common Stock | 2.82 | 2.815 | 2.813 | 2.811 | 2.809 |
| Additional Paid-In Capital | 2691.84 | 2664.74 | 2645.37 | 2631.11 | 2617.94 |
| Retained Earnings (Accumulated Deficit) | -2585.34 | -2532.41 | -2476.54 | -2443.26 | -2381.1 |
| Unrealized Gain (Loss) | -0.201 | -0.116 | -0.354 | -0.637 | -0.608 |
| Other Equity, Total | -6.543 | -11.989 | -38.724 | -16.603 | -0.42 |
| Total Liabilities & Shareholders’ Equity | 700.519 | 724.167 | 759.528 | 800.589 | 826.938 |
| Total Common Shares Outstanding | 283.301 | 281.108 | 280.887 | 280.457 | 280.134 |
- Výročný
- Štvrťročne
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Čistý príjem/Počiatočná čiara | -236.568 | -250.46 | -276.852 | -356.388 | -348.995 |
| Hotovosť z prevádzkovej činnosti | -166.575 | -202.491 | -233.29 | -250.416 | -299.955 |
| Hotovosť z prevádzkovej činnosti | 5.342 | 6.209 | 8.846 | 4.775 | 4.216 |
| Deferred Taxes | 0.009 | 0.034 | -0.155 | -1.415 | 0 |
| Bezhotovostné položky | 104.522 | 70.664 | 66.935 | 91.002 | 49.551 |
| Úroky zaplatené v hotovosti | 34.358 | 30.468 | 24.683 | 16.966 | 7.5 |
| Zmeny pracovného kapitálu | -39.88 | -28.938 | -32.064 | 11.61 | -4.727 |
| Peniaze z investičných činností | 92.316 | 78.761 | -13.579 | 95.153 | -121.2 |
| Kapitálové výdavky | -3.766 | -3.884 | -3.227 | -20.012 | -6.308 |
| Ostatné investičné položky peňažných tokov, celkom | 96.082 | 82.645 | -10.352 | 115.165 | -114.892 |
| Hotovosť z finančných činností | -7.463 | 212.073 | 262.858 | 217.502 | 450.775 |
| Financovanie položiek peňažných tokov | -11.49 | -16.656 | -10.028 | 16.64 | -2.832 |
| Vydanie (vyradenie) zásob, netto | 4.31 | 229.208 | 42.282 | 201.282 | 307.345 |
| Vydanie (vyradenie) dlhu, netto | -0.283 | -0.479 | 230.604 | -0.42 | 146.262 |
| Devízové efekty | -14.619 | -5.049 | 3.83 | 1.729 | 1.518 |
| Čistá zmena v hotovosti | -96.341 | 83.294 | 19.819 | 63.968 | 31.138 |
| Cash Taxes Paid | 1.609 | 20.032 | 10.371 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -52.932 | -236.568 | -180.703 | -147.417 | -85.26 |
| Cash From Operating Activities | -18.069 | -166.575 | -85.803 | -74.177 | -58.315 |
| Cash From Operating Activities | 1.257 | 5.342 | 4.031 | 2.745 | 1.411 |
| Non-Cash Items | 41.697 | 104.522 | 79.442 | 55.954 | 37.389 |
| Cash Taxes Paid | 0.178 | 1.609 | 0.935 | 0.71 | 0.456 |
| Cash Interest Paid | 11.361 | 34.358 | 24.058 | 15.108 | 7.509 |
| Changes in Working Capital | -3.152 | -39.88 | 11.427 | 14.541 | -11.855 |
| Cash From Investing Activities | 36.255 | 92.316 | 159.02 | 84.505 | 58.213 |
| Capital Expenditures | -1.942 | -3.766 | -1.089 | -1.226 | -0.871 |
| Other Investing Cash Flow Items, Total | 38.197 | 96.082 | 160.109 | 85.731 | 59.084 |
| Cash From Financing Activities | -7.825 | -7.463 | -8.02 | -7.461 | -8.154 |
| Financing Cash Flow Items | -10.452 | -11.49 | -11.119 | -9.278 | -8.993 |
| Issuance (Retirement) of Stock, Net | 2.655 | 4.31 | 3.191 | 1.858 | 0.859 |
| Issuance (Retirement) of Debt, Net | -0.028 | -0.283 | -0.092 | -0.041 | -0.02 |
| Foreign Exchange Effects | 1.507 | -14.619 | -33.12 | -12.462 | -3.377 |
| Net Change in Cash | 11.868 | -96.341 | 32.077 | -9.595 | -11.633 |
| Deferred Taxes | -4.939 | 0.009 |
| Meno investora | Typ investora | Percento vynikajúce | Držané akcie | Zmena akcií | Dátum držby | Hodnotenie obratu |
|---|---|---|---|---|---|---|
| Perceptive Advisors LLC | Private Equity | 9.7208 | 27662917 | 20000 | 2023-03-31 | MED |
| Avoro Capital Advisors LLC | Investment Advisor/Hedge Fund | 9.5932 | 27300000 | 500000 | 2023-03-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 9.4244 | 26819529 | 323574 | 2023-03-31 | LOW |
| Redmile Group, LLC | Investment Advisor/Hedge Fund | 6.4471 | 18346861 | -1902928 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.2531 | 17794935 | -462246 | 2023-03-31 | LOW |
| Janus Henderson Investors | Investment Advisor/Hedge Fund | 4.7827 | 13610435 | -84114 | 2023-03-31 | LOW |
| Morgan Stanley & Co. LLC | Research Firm | 4.2773 | 12172065 | -2396638 | 2023-03-31 | MED |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 3.9114 | 11130885 | -954954 | 2023-03-31 | LOW |
| Palo Alto Investors LP | Hedge Fund | 3.6981 | 10524022 | 30300 | 2023-03-31 | LOW |
| Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 3.5087 | 9984901 | 1553949 | 2023-03-31 | LOW |
| Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 2.6408 | 7515041 | -592306 | 2023-03-31 | LOW |
| JP Morgan Asset Management | Investment Advisor | 2.5262 | 7188898 | 460005 | 2023-03-31 | LOW |
| Macquarie Investment Management | Investment Advisor | 2.5199 | 7171035 | 212988 | 2023-03-31 | LOW |
| JPMorgan Asset Management U.K. Limited | Investment Advisor/Hedge Fund | 2.061 | 5865111 | -7089 | 2023-03-31 | LOW |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 1.8976 | 5400086 | 2934928 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.807 | 5142407 | 251979 | 2023-03-31 | LOW |
| Fiera Capital Corporation | Investment Advisor/Hedge Fund | 1.7926 | 5101364 | -87793 | 2023-03-31 | LOW |
| Invus Public Equities Advisors, LLC | Investment Advisor | 1.2392 | 3526407 | -473593 | 2023-03-31 | LOW |
| Boxer Capital, L.L.C. | Hedge Fund | 0.817 | 2325000 | 0 | 2023-03-31 | LOW |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.8065 | 2295225 | 20644 | 2023-03-31 | LOW |
Prečo si vybrať Capital.com? Naše čísla hovoria samy za seba.
Capital.com Group535K+
Obchodníci
87K+
Aktívni klienti za mesia
$113M+
Mesačný objem investícií
$64M+
Výbery každý mesiac
Obchodná kalkulačka
Vypočítajte si svoj hypotetický zisk a stratu, ak ste otvorili obchod s CFD v určitý deň (vyberte dátum) a uzavreli v iný dátum (vyberte dátum).
Obchodná provízia
0
- 1:1
Leverage (pákový efekt)
1:1
- 20
- 100
- 500
- 1000
- 10000
Investície
Veľkosť obchodu (pákový efekt x investície):
Otvorenie
Zatvorenie
Krátke Dlhé
Amicus Company profile
O spoločnosti Amicus
Amicus Therapeutics, Inc. je globálna biotechnologická spoločnosť, ktorá sa zameriava na objavovanie, vývoj a dodávanie liekov na zriedkavé choroby. V portfóliu spoločnosti je Galafold (migalastat), ktorý je schváleným perorálnym presným liekom pre ľudí žijúcich s Fabryho chorobou. Migalastat je schválený pod obchodným názvom Galafold v Spojených štátoch, Európskej únii, Spojenom kráľovstve a Japonsku. Jej pripravovaným biologickým programom je Amicus Therapeutics GAA (AT-GAA), ktorý je paradigmou liečby Pompeho choroby v klinickej fáze. Úrad pre kontrolu potravín a liečiv Spojených štátov amerických (FDA) udelil lieku AT-GAA označenie Breakthrough Therapy (BTD) na liečbu neskorého nástupu Pompeho choroby. Jej portfólio zahŕňa programy génovej terapie zriedkavých neurologických lyzozomálnych porúch (LD), konkrétne: CLN6, CLN3 a CLN1 Battenova choroba, Pompeho choroba, Fabryho choroba, porucha z nedostatku CDKL5 (CDD), mukopolysacharidóza typu IIIB (MPS IIIB), ako aj mukopolysacharidóza typu IIIA (MPS IIIA).
| Industry: | Biotechnology & Medical Research (NEC) |
3675 Market Street
PHILADELPHIA
PENNSYLVANIA 19104
US
Výkaz ziskov a strát
- Annual
- Quarterly
Ľudia tiež sledujú
Stále hľadáte brokera, ktorému sa dá veriť?
Pridajte sa k 535 000 obchodníkom na celom svete, ktorí sa rozhodli obchodovať s Capital.com